Research update: ‘BATCure’ receives an EU Horizon 2020 grant

Orphazyme is proud to participate in the BATCure consortium which has been established to investigate potential therapies for Batten’s disease and related lysosomal diseases.

BATCure has been awarded an EU Horizon 2020 grant of close to 6 million Euro, which will enable the syndicate of leading scientific groups and companies to significantly advance the development of new therapies for Batten’s disease.

The BATCure consortium is organized by Dr Sara Mole, University College London.

Further information: 
Thomas Kirkegaard Jensen, CSO at Orphazyme ApS
E-mail: tkj@orphazyme.com

About Orphazyme

Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program, arimoclomol, is entering clinical development as a treatment for Niemann-Pick disease type C (NP-C). NP-C and Battens’s disease are both lysosomal diseases, a family of more than 50 genetic diseases. For more information, please visit www.orphazyme.com.